{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:20Z","timestamp":1790916980951,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01233-0","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T07:58:55Z","timestamp":1786003135000},"page":"635-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4\/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+\/HER2\u2212 Metastatic Breast Cancer in the USA\u2014A Vodcast"],"prefix":"10.1007","volume":"21","author":[{"given":"Hope S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne C.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"1","key":"1233_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in the US real-world setting. ESMO Open. 2025;10(1):104103. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104103.","journal-title":"ESMO Open"},{"issue":"9","key":"1233_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105570","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO Open. 2025;10(9):105570. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105570.","journal-title":"ESMO Open"},{"key":"1233_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756.","journal-title":"Breast"},{"key":"1233_CR4","doi-asserted-by":"publisher","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines(R) insights: breast cancer, version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594\u2013608. https:\/\/doi.org\/10.6004\/jnccn.2023.0031.","DOI":"10.6004\/jnccn.2023.0031"},{"key":"1233_CR5","unstructured":"U.S. Food and Drug Administration. Kisqali (ribociclib)\u2014prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209092s019lbl.pdf. Accessed 19 Aug 2024."},{"key":"1233_CR6","unstructured":"U.S. Food and Drug Administration. Ibrance (palbociclib)\u2014prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212436s005s006lbl.pdf. Accessed 19 Aug 2024."},{"key":"1233_CR7","unstructured":"U.S. Food and Drug Administration. Verzenio (abemaciclib)\u2014prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208716s010s011lbl.pdf. Accessed 19 Aug 2024."},{"issue":"20","key":"1233_CR8","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"issue":"32","key":"1233_CR9","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1233_CR10","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"issue":"8","key":"1233_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35(8):718\u201327. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.013.","journal-title":"Ann Oncol"},{"issue":"10","key":"1233_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2114663.","journal-title":"N Engl J Med"},{"issue":"9","key":"1233_CR13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Dieras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42(9):994\u20131000. https:\/\/doi.org\/10.1200\/JCO.23.00137.","journal-title":"J Clin Oncol"},{"key":"1233_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.breast.2020.10.005","volume":"54","author":"A Batra","year":"2020","unstructured":"Batra A, Kong S, Cheung WY. Eligibility of real-world patients with metastatic breast cancer for clinical trials. Breast. 2020;54:171\u20138. https:\/\/doi.org\/10.1016\/j.breast.2020.10.005.","journal-title":"Breast"},{"issue":"2","key":"1233_CR15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/curroncol30020143","volume":"30","author":"M Tang","year":"2023","unstructured":"Tang M, Pearson SA, Simes RJ, Chua BH. Harnessing real-world evidence to advance cancer research. Curr Oncol. 2023;30(2):1844\u201359. https:\/\/doi.org\/10.3390\/curroncol30020143.","journal-title":"Curr Oncol"},{"key":"1233_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.breast.2021.12.015","volume":"61","author":"P Cottu","year":"2022","unstructured":"Cottu P, Ramsey SD, Sol\u00e0-Morales O, Spears PA, Taylor L. The emerging role of real-world data in advanced breast cancer therapy: recommendations for collaborative decision-making. Breast. 2022;61:118\u201322. https:\/\/doi.org\/10.1016\/j.breast.2021.12.015.","journal-title":"Breast"},{"issue":"5","key":"1233_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","volume":"16","author":"CM Booth","year":"2019","unstructured":"Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16(5):312\u201325. https:\/\/doi.org\/10.1038\/s41571-019-0167-7.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1233_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/fon-2022-1287","volume":"19","author":"S Kahraman","year":"2023","unstructured":"Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, et al. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive\/HER2-negative metastatic breast cancer. Future Oncol. 2023;19(10):727\u201336. https:\/\/doi.org\/10.2217\/fon-2022-1287.","journal-title":"Future Oncol"},{"key":"1233_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1203684","volume":"13","author":"NH Al-Ziftawi","year":"2023","unstructured":"Al-Ziftawi NH, Elazzazy S, Alam MF, Shafie A, Hamad A, Bbujassoum S, et al. The effectiveness and safety of palbociclib and ribociclib in stage IV HR+\/HER2-negative breast cancer: a nationwide real world comparative retrospective cohort study. Front Oncol. 2023;13:1203684. https:\/\/doi.org\/10.3389\/fonc.2023.1203684.","journal-title":"Front Oncol"},{"issue":"1","key":"1233_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-024-00070-w","volume":"2","author":"ML Gehrchen","year":"2024","unstructured":"Gehrchen ML, Berg T, Garly R, Jensen M-B, E\u00dfer-Naumann S, R\u00f8nlev JD, et al. Real-world effectiveness of CDK 4\/6 inhibitors in estrogen-positive metastatic breast cancer. BJC Rep. 2024;2(1):44. https:\/\/doi.org\/10.1038\/s44276-024-00070-w.","journal-title":"BJC Rep"},{"issue":"11","key":"1233_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13111938","volume":"13","author":"AI Miron","year":"2023","unstructured":"Miron AI, Anghel AV, Barnonschi AA, Mitre R, Liscu HD, G\u0103inariu E, et al. Real-world outcomes of CDK4\/6 inhibitors treatment in metastatic breast cancer in Romania. Diagnostics (Basel). 2023;13(11):1938. https:\/\/doi.org\/10.3390\/diagnostics13111938.","journal-title":"Diagnostics (Basel)"},{"issue":"21","key":"1233_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215164","volume":"15","author":"H Tang","year":"2023","unstructured":"Tang H, Yeo D, De Souza K, Ahmad O, Shafiq T, Ofor O, et al. Clinical impact of CDK4\/6 inhibitors in de novo or PR- or very elderly post-menopausal ER+\/HER2\u2212 advanced breast cancers. Cancers (Basel). 2023;15(21):5164. https:\/\/doi.org\/10.3390\/cancers15215164.","journal-title":"Cancers (Basel)"},{"key":"1233_CR23","doi-asserted-by":"publisher","unstructured":"Thill M, Zahn M-O, Welt A, Nusch A, Zaiss M, Engelken K, et al. Palbociclib versus ribociclib in first-line treatment of patients with hormone-receptor positive HER2 negative advanced breast cancer\u2014real world outcome data from the German registry platform OPAL. Cancer Res. 2024;84(suppl 9):PO1-04-12. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-po1-04-12.","DOI":"10.1158\/1538-7445.Sabcs23-po1-04-12"},{"issue":"10","key":"1233_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108488","volume":"24","author":"M Cejuela","year":"2023","unstructured":"Cejuela M, Gil-Torralvo A, Castilla MA, Dominguez-Cejudo MA, Falcon A, Benavent M, et al. Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int J Mol Sci. 2023;24(10):8488. https:\/\/doi.org\/10.3390\/ijms24108488.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1233_CR25","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1177\/10781552231163121","volume":"29","author":"W Buller","year":"2023","unstructured":"Buller W, Pallan L, Chu T, Khoja L. CDK4\/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset. J Oncol Pharm Pract. 2023;29(8):1825\u201335. https:\/\/doi.org\/10.1177\/10781552231163121.","journal-title":"J Oncol Pharm Pract"},{"issue":"suppl 16","key":"1233_CR26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.2024.42.16_suppl.1014","volume":"42","author":"C Vernieri","year":"2024","unstructured":"Vernieri C, Provenzano L, Guiliano M. Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+\/HER2\u2212 aBC: results of the multicenter, real-world, Italian study PALMARES-2. J Clin Oncol. 2024;42(suppl 16):1014. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1014.","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"1233_CR27","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.1016\/j.annonc.2023.09.624","volume":"34","author":"HMA Abdallah","year":"2023","unstructured":"Abdallah HMA, Owoseni YI, Sultan A, Ahmed S, Wood J, Varadhan B, et al. 448P Real-world experience with CDK4\/6 inhibitors for HR+\/HER2-metastatic breast cancer (MBC). Ann Oncol. 2023;34(suppl 2):S369\u201370. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.624.","journal-title":"Ann Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01233-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:52:00Z","timestamp":1790916720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01233-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01233-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hope S. Rugo reports a consulting or advisory role for Napo, Bristol Myers Squibb, Helsinn, and BioNTech; institutional research funding to her prior institution (UCSF) from AstraZeneca, Gilead Sciences Inc., Lilly, Merck & Co., Daiichi Sankyo Inc., Novartis Pharmaceuticals, Pfizer Inc., F. Hoffman-La Roche\/AG\/Genentech, Stemline Therapeutics, and Ambryx; and institutional research funding to City of Hope from Bicycle Therapeutics, F. Hoffman-La Roche\/AG\/Genentech, Merck, PhoenixMD, and Stemline Therapeutics. Joanne C. Ryan is an employee of and stockholder in Pfizer Inc.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}